Bardia, Aditya Hu, Xichun Dent, Rebecca Yonemori, Kan Barrios, Carlos H O'Shaughnessy, Joyce A Wildiers, Hans Pierga, Jean-Yves Zhang, Qingyuan Saura, Cristina
...
BACKGROUND: Outcomes in patients with hormone receptor-positive metastatic breast cancer worsen after one or more lines of endocrine-based therapy. Trastuzumab deruxtecan has shown efficacy in patients with metastatic breast cancer with low expression of human epidermal growth factor receptor 2 (HER2) after previous chemotherapy. METHODS: We conduc...
Rugo, Hope Schmid, Peter Tolaney, Sara Dalenc, Florence Marmé, Frederik Shi, Ling Verret, Wendy Shah, Anuj Gharaibeh, Mahdi Bardia, Aditya
...
BACKGROUND: The TROPiCS-02 study (NCT03901339) demonstrated that sacituzumab govitecan (SG) has superior clinical outcomes over treatment of physicians choice (TPC) chemotherapy in patients with hormone receptor-positive, human epidermal growth factor 2 receptor-negative (HR+/HER2-) metastatic breast cancer (mBC). Here, we present health-related qu...
Jung, Jinkyu Schneider, Eric Zhang, Wei Song, Hua Zhang, Meili Chou, William Meher, Niranjan VanBrocklin, Henry Barcellos-Hoff, Mary Helen Ozawa, Tomoko
...
Central nervous system tumors have resisted effective chemotherapy because most therapeutics do not penetrate the blood-tumor-brain-barrier. Nanomedicines between ~ 10 and 100 nm accumulate in many solid tumors by the enhanced permeability and retention effect, but it is controversial whether the effect can be exploited for treatment of brain tumor...
Tolaney, Sara Loirat, Delphine Punie, Kevin Oliveira, Mafalda Brufsky, Adam Kalinsky, Kevin Cortés, Javier Shaughnessy, Joyce Diéras, Véronique Carey, Lisa
...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO ...
El-Sayed, Ashraf S. A. ElSayed, Abdelaleim I. Wadan, Khalid M. El-Saadany, Sayed S. Abd El-Hady, Nouran A. A.
Published in
Microbial Cell Factories
Attenuation of camptothecin (CPT) productivity by fungi with preservation and subculturing is the challenge that halts fungi to be an industrial platform of CPT production. Thus, screening for novel endophytic fungal isolates with metabolic stability for CPT production was the objective. Catharanthus roseus is one of the medicinal plants with diver...
Kelliher, Jessica L Folkerts, Melissa L Shen, Kaiyuan V Song, Wan Tengler, Kyle Stiefel, Clara M Lee, Seong-Ok Dray, Eloise Zhao, Weixing Koss, Brian
...
The master DNA damage repair histone protein, H2AX, is essential for orchestrating the recruitment of downstream mediator and effector proteins at damaged chromatin. The phosphorylation of H2AX at S139, γH2AX, is well-studied for its DNA repair function. However, the extended C-terminal tail is not characterized. Here, we define the minimal motif o...
Yu, Changjun Huang, Faqing Wang, Kinsley Liu, Mengmeng Chow, Warren Ling, Xiang Li, Fengzhi Causey, Jason Huang, Xiuzhen Cook-Wiens, Galen
...
BACKGROUND: The alkaloid camptothecin analog SN38 is a potent antineoplastic agent, but cannot be used directly for clinical application due to its poor water solubility. Currently, the prodrug approach on SN38 has resulted in 3 FDA-approved cancer therapeutics, irinotecan, ONIVYDE, and Trodelvy. However, only 2-8% of irinotecan can be transformed ...
Wang, Xianzhang Zhuang, Yumeng Wang, Yuankun Jiang, Maokai Yao, Lei
Published in
European journal of medicinal chemistry
This review article focuses on the research progress made in the structural modifications of camptothecin (CPT), a potent cytotoxic natural alkaloid. CPT possesses a unique 5-fused ring structure and exhibits various beneficial activities such as anti-proliferative, anti-fungal, insecticidal, and anti-SARS-CoV-2 properties. CPT and its analogs, inc...
Guha Majumdar, Ananda Shree, Shikha Das, Amit Kumar, Binita K Dey, Papiya Subramanian, Mahesh Patro, Birija Sankar
Published in
European journal of medicinal chemistry
Combinatorial inhibition of Topoisomerase 1 (TOP1) and Poly (ADP-ribose) polymerase 1 (PARP1) is an attractive therapeutic strategy which is under active investigation to address chemoresistance to TOP1 inhibitors. However, this combinatorial regimen suffers from severe dose limiting toxicities. Dual inhibitors often offer significant advantages ov...
Xie, Jiacui Wang, He Huang, Qiudi Lin, Jiachang Wen, Huaying Miao, Yingling Lv, Le Ruan, Dongxue Yu, Xiyong Qin, Linghao
...
Published in
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Delivering traditional DNA-damaging anticancer drugs into mitochondria to damage mitochondria is a promising chemotherapy strategy. The impermeability of this mitochondrial inner membrane, however, impedes the delivery of drug molecules that could impact other important biological roles of mitochondria. Herein, the prodrug camptothecin (CPT)-triphe...